Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI. The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosed NSCLC or SCLC;
• Patient treated priorly by ICI and progressed under ICI;
• Have provided written informed consent for the study;
• Be \>/= 18 years of age on day of signing informed consent.
Locations
Other Locations
France
Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
RECRUITING
Boulogne-billancourt
Contact Information
Primary
Etienne Giroux Leprieur, MD, PhD
etienne.giroux-leprieur@aphp.fr
+33 1 49 09 58 02
Time Frame
Start Date: 2020-08-18
Estimated Completion Date: 2027-08
Participants
Target number of participants: 50
Treatments
Experimental: Rebiopsy
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris